Five Things you Can Do Right Now to Protect your Health System Pharmacy from Cyber Intrusions


Cyber intrusions continue to plague health care organizations and the impact has been heightened during the COVID-19 pandemic as resources and personnel are stretched thin and cyber attackers take advantage of increased vulnerabilities. As we move through the pandemic, we expect the rate and severity of cyber intrusions to rise. Here are five steps that pharmacy leaders can now to prepare and protect against cyber intrusions as well as to limit the impact when they occur.


It’s Time for Commonsense Drug Pricing Solutions


A cheer went up among Vizient and our members last year when HHS announced the termination of the FDA’s Unapproved Drugs Initiative to curb rising drug costs. Our analysis found that ending the program could protect the U.S. health care system from an additional $7.52 billion of cost. Read why Vizient is advocating for commonsense drug pricing solutions as the Biden Administration and federal regulatory agencies may soon take up the issue.


Use of Monoclonal Antibody Therapy Continues to Advance


One of the more recent advancements in pharmaceuticals has been transformative to the management of disease is the discovery and utilization of “monoclonal antibodies” (mAb). Its impact cannot be overstated. Learn more about how mAbs are also playing critical roles, including the fight against COVID-19. 


Managing COVID-19 Testing Demands in your Health System: Key Considerations for CFOs Before Investing in New Technology


The drum beat for managing the COVID-19 pandemic from public health leaders continues to be test, test, test. Before investing in new technology, there are several considerations that chief financial officers should consider.


Getting the Best Pricing for Reference Laboratory Services


The COVID pandemic has produced many new challenges for hospital-based laboratories. One area that laboratory leaders may find immediate cost reduction opportunities is through a review of utilization and pricing for reference laboratory services. 


Our National Lab Experiment: Testing for the SARS-CoV-2 Coronavirus


As a nurse with decades of experience, I have been perplexed by the ongoing reporting challenges related to testing for COVID-19. There are a multitude of vendors providing the various tests that determine if a patient is infected with the active virus and those that detect antibodies that indicate prior infection. There is a broad variation in turnaround time for results — from a few hours to a few days to even weeks for some. It is an unprecedented health care issue with an unprecedented response.


COVID-19 Response Requires Innovation from Hospital Labs: 4 Actions to Take Now


At the beginning of the COVID-19 pandemic, medical laboratories immediately experienced a decline in testing volume. And, while the test volumes are inching upward as labs find their footing in the new pandemic environment, the rate of recovery is slower than anticipated.


Chronic Pain Doesn’t Go Away During a Pandemic. Here’s How to Develop a Program to Connect These Patients Back to the Care They Need


With over 50 million U.S. adults experiencing chronic pain daily, the need for patient care hasn’t disappeared, but it may have grown more complicated due to the pandemic.   


Drug Importation, eh?

[Full disclosure: your author is a Canadian import] After several months of D.C. chatter and countless state importation bills, FDA recently took two significant regulatory steps to allow for prescription drug importation from Canada. Wait, you thought importation was already happening in Florida? Not quite. More

USP Regulatory Updates Delayed on Appeal

We’ve recently shared communications about updates to existing United States Pharmacopeia Convention (USP) Chapters surrounding pharmaceutical compounding regulations as well as a new regulation for handling hazardous drugs in health care facilities. The new and updated rules were scheduled to go into effect Dec. 1. More